Evidence map›Paper›PMID 35018664›Full record

ArticleJournal of clinical pharmacy and therapeutics2022

Dramatic clinical response in the treatment of small cell glioblastoma multiforme.

Farzana Yasmin Zaman, Catriona McLean, Malaka Ameratunga

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pharmacy and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Farzana Yasmin ZamanDepartment of Medical Oncology, The Alfred Hospital, Melbourne, Vic, Australia.ORCID https://orcid.org/0000-0002-2095-0850
Catriona McLeanDepartment of Anatomical Pathology, The Alfred Hospital, Melbourne, Vic, Australia.
Malaka AmeratungaDepartment of Medical Oncology, The Alfred Hospital, Melbourne, Vic, Australia.ORCID https://orcid.org/0000-0002-7171-6781
The Alfred Hospital · AUFlorey Institute of Neuroscience and Mental Health · AU

Funding

Monash University
6 · The paper itself

Abstract

WHAT IS KNOWN AND

objectiveSmall cell glioblastoma (scGBM) is a rare subtype of primary glioblastoma, which typically behave more aggressively compared with classical glioblastoma (GBMs). They are generally associated with poor responses to treatment, and optimal treatment is not known. CASE SUMMARY: We present the case of a 51-year-old woman with scGBM with O WHAT IS NEW AND

conclusionThis case highlights that treatment with temozolomide-based chemoradiotherapy is justified in patients with scGBM, despite their poor prognosis. MGMT methylation may be associated with clinical responses.

Indexed as

Brain NeoplasmsGlioblastomaDacarbazineDNA MethylationFemaleHumansMiddle AgedO(6)-Methylguanine-DNA MethyltransferasePrognosisDacarbazineO(6)-Methylguanine-DNA Methyltransferasechemoradiotherapysmall cell glioblastoma multiformetemozolomide

Identifiers

PMID35018664
PMCPMC9303203
OpenAlexW4206167979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.